ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ENTA vs IRD // EV/EBITDA & P/E VALUATION

Enanta Pharmaceuticals Inc. (NASDAQ) VS. Opus Genetics Inc. (NASDAQ) • 15-METRIC TALLY: ENTA 2 — IRD 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENTA VS. IRD) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ENTA IRD SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -9.91% -11.61% +1.70 ENTA /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -3.40% 29.10% -32.50 IRD /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 IRD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.6 39.7 -3.05 IRD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $324.7M $303.7M $21.1M ENTA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ENTA REV IRD REV ENTA GROSS % IRD GROSS % ENTA FCF IRD FCF
FY 2025 $65.3M $14.2M — — -$32.2M -$35.3M
FY 2024 $67.6M $11.0M — — -$96.7M -$25.6M
FY 2023 $79.2M $19.0M — — -$103.2M -$1.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENTA // BETA —
IRD // BETA —